Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (83,354)	$ (61,714)
Adjustments to reconcile net loss to net cash used in operating activities:
Issuance of common stock for in-process research and development expense	0	3,787
Stock-based compensation	11,304	6,468
Depreciation and amortization	150	141
Non-cash lease expense	228	24
Change in fair value of warrant liability	(9,866)	(332)
Amortization of premium on marketable securities	4,099	2,989
Realized loss (gain) on marketable securities	1,099	(56)
Net loss on disposal of property and equipment	32	0
Change in operating assets and liabilities (net of assets and liabilities acquired in the Merger)
Prepaid expenses and other current assets	(1,452)	(1,788)
Interest receivable on marketable securities	689	(722)
Lease security deposit	283	0
Accounts payable	(930)	3,034
Accrued expenses	(2,221)	3,461
Net cash used in operating activities	(79,939)	(44,708)
Cash flow from investing activities:
Purchases of marketable securities	(382,598)	(354,848)
Proceeds from sale of marketable securities	468,182	89,590
Purchases of property and equipment	(305)	(147)
Proceeds from sale of property and equipment	7	0
Net cash provided by (used in) investing activities	85,286	(265,405)
Cash flow from financing activities:
Proceeds from the Merger, net of offering costs paid	0	624,769
Proceeds from issuance of common stock under ESPP	292	0
Proceeds from exercises of options	628	220
Net cash provided by financing activities	920	624,989
Net increase in cash and cash equivalents	6,267	314,876
Cash and cash equivalents, beginning of the period	132,423	29,755
Cash and cash equivalents, end of the period	138,690	344,631
Non-cash operating activities
Right-of-use assets recognized	2,171	3,917
Operating lease liabilities recognized	2,171	4,074
Reclassification of deferred rent	0	(157)
Non-cash investing and financing activities:
Purchase of property and equipment included in accounts payable	0	66
Issuance of common stock for in-process research and development	0	3,787
Issuance costs from Business Merger in account payable and accrued expenses	$ 0	$ 62